Last reviewed · How we verify
STP1002
At a glance
| Generic name | STP1002 |
|---|---|
| Also known as | Basroparib |
| Sponsor | ST Pharm Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- First-In-Human Dose-Escalation Study of STP1002 in Patients With Advanced-Stage Solid Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- STP1002 CI brief — competitive landscape report
- STP1002 updates RSS · CI watch RSS
- ST Pharm Co., Ltd. portfolio CI